Kennedy Robert Eugene 4
4 · RXI PHARMACEUTICALS CORP · Filed Apr 22, 2011
Insider Transaction Report
Form 4
Kennedy Robert Eugene
Vice President and CFO
Transactions
- Award
Common Stock
2011-04-13+374,288→ 374,288 total - Award
Common Stock
2011-04-13+2,430→ 376,718 total(indirect: By Spouse) - Award
Common Stock
2011-04-13+2,576→ 379,294 total(indirect: By LLC) - Award
Stock Option
2011-04-13+30,000→ 30,000 totalExercise: $1.27Exp: 2021-04-12→ Common Stock (30,000 underlying)
Footnotes (7)
- [F1]Received in exchange for 3,078,013 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.
- [F2]Received in exchange for 20,000 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.
- [F3]The reporting person is a managing member of the LLC that owns the reporting securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F4]Received in exchange for 21,200 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.
- [F5]Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.
- [F6]Per share.
- [F7]1,250 of the options vested on July 13, 2011, with the remaining shares vesting in equal installments on each of the next 11 quarterly anniversaries of July 13, 2011.